| Abstrakt: |
5ht3 Receptor Antagonists, Acetanilides, Antiarrhythmic Agents, Antiemetic-Antivertigo Agents, Cardiovascular Agents, Central Nervous System Agents, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, General Anesthetics, Health and Medicine, Lidocaine, Lidocaine Therapy, Local Injectable Anesthetics, Neurologic Manifestations, Ondansetron Therapy, Ophthalmic Anesthetics, Ophthalmic Preparations, Pain, Pharmaceuticals, Phenols, Post-Operative Pain, Propofol, Propofol Therapy, Risk and Prevention Keywords: 5ht3 Receptor Antagonists; Acetanilides; Antiarrhythmic Agents; Antiemetic-Antivertigo Agents; Cardiovascular Agents; Central Nervous System Agents; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; General Anesthetics; Health and Medicine; Lidocaine; Lidocaine Therapy; Local Injectable Anesthetics; Neurologic Manifestations; Ondansetron Therapy; Ophthalmic Anesthetics; Ophthalmic Preparations; Pain; Pharmaceuticals; Phenols; Post-Operative Pain; Propofol; Propofol Therapy; Risk and Prevention EN 5ht3 Receptor Antagonists Acetanilides Antiarrhythmic Agents Antiemetic-Antivertigo Agents Cardiovascular Agents Central Nervous System Agents Clinical Research Clinical Trials and Studies Drugs and Therapies General Anesthetics Health and Medicine Lidocaine Lidocaine Therapy Local Injectable Anesthetics Neurologic Manifestations Ondansetron Therapy Ophthalmic Anesthetics Ophthalmic Preparations Pain Pharmaceuticals Phenols Post-Operative Pain Propofol Propofol Therapy Risk and Prevention 1411 1411 1 10/09/23 20231009 NES 231009 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on pain is the subject of a new report. [Extracted from the article] |
